Concepedia

Mark E. Morrison

ME

5

Publications

966

Citations

5

H-Index

1983

Active since

Affiliations

UNC Lineberger Comprehensive Cancer Center(Current)

Mark E. Morrison is an author at UNC Lineberger Comprehensive Cancer Center specializing in medicine, drug discovery, and tumor biology.

Top concepts

Publications per year

1983–2006

5

Publications

5

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

Nasser H. Hanna, Paul A. Bunn, Corey J. Langer et al. · Journal of Clinical Oncology · 2006 · 673 citations · Full text

A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase.

Mark E. Morrison, Dov Engelstein, Anthony P. Albino et al. · The Journal of Experimental Medicine · 1993 · 174 citations · Full text

, , +22

Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung Cancer

Rogério Lilenbaum, Mark A. Socinski, Nasser K. Altorki et al. · Journal of Clinical Oncology · 2006 · 61 citations · Full text

In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells.

Mark E. Morrison, Mary Jane Yagi, G. Cohen · Proceedings of the National Academy of Sciences · 1985 · 41 citations · Full text

, , +19

Novel substrates for tyrosinase serve as precursors of 6-hydroxydopamine and 6-hydroxydopa

Mark E. Morrison, Gerald Cohen · Biochemistry · 1983 · 17 citations

, , +19

Rows per page

1–5 of 5